CytoSorbents Corporation, a leader in blood purification treatment for life-threatening conditions, has released its financial results for the first quarter of 2025, ending March 31. The company reported a product revenue of $8.7 million, reflecting a 3% decrease from $9.0 million in the first quarter of 2024. On a constant currency basis, product revenue remained flat. Gross margin decreased to 71% from 77% in the corresponding quarter of the previous year. However, the operating loss improved by 17% to $3.9 million, down from $4.7 million in Q1 2024, thanks to a 12% reduction in operating expenses. Additionally, the company received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss and R&D tax credits. In terms of business highlights, CytoSorbents completed a Shareholder Rights Offering, raising $6.8 million in net proceeds, and released $5.0 million of restricted cash, enhancing liquidity by a total of $11.8 million. The company also expanded its global presence by opening a regional sales subsidiary in Dubai, United Arab Emirates, and appointed Thomas Shannon as Vice President of Marketing for North America and Melanie Grossman, CPA, as Vice President and Corporate Controller.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.